BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 17492455)

  • 1. Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature.
    Weberschock TB; Müller SM; Boehncke S; Boehncke WH
    Arch Dermatol Res; 2007 Jul; 299(4):169-75. PubMed ID: 17492455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR; Butler KA; Wallace RL; Smith SM; Harirforoosh S
    J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA; Derry S; McQuay HJ
    BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
    Hur C; Chan AT; Tramontano AC; Gazelle GS
    Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory drugs in the 21st century.
    Rainsford KD
    Subcell Biochem; 2007; 42():3-27. PubMed ID: 17612044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of the cardiovascular safety of COXIBs compared to NSAIDS.
    Moodley I
    Cardiovasc J Afr; 2008; 19(2):102-7. PubMed ID: 18516356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs)].
    Boehncke S; Boehncke WH
    Dtsch Med Wochenschr; 2005 Oct; 130(40):2249-52. PubMed ID: 16208597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral cyclo-oxygenase 2 inhibitors versus other oral analgesics for acute soft tissue injury: systematic review and meta-analysis.
    Jones P; Lamdin R
    Clin Drug Investig; 2010; 30(7):419-37. PubMed ID: 20527999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
    Moore RA; Derry S; Phillips CJ; McQuay HJ
    BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP; Deray G; Héloire F
    Presse Med; 2006 Sep; 35 Suppl 1():25-34. PubMed ID: 17870550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coxibs: a significant therapeutic opportunity.
    Gatti D; Adami S
    Acta Biomed; 2010 Dec; 81(3):217-24. PubMed ID: 22530460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
    Lanas A; Ferrandez A
    Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis.
    Spiegel BM; Farid M; Dulai GS; Gralnek IM; Kanwal F
    Am J Med; 2006 May; 119(5):448.e27-36. PubMed ID: 16651060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    ; Bhala N; Emberson J; Merhi A; Abramson S; Arber N; Baron JA; Bombardier C; Cannon C; Farkouh ME; FitzGerald GA; Goss P; Halls H; Hawk E; Hawkey C; Hennekens C; Hochberg M; Holland LE; Kearney PM; Laine L; Lanas A; Lance P; Laupacis A; Oates J; Patrono C; Schnitzer TJ; Solomon S; Tugwell P; Wilson K; Wittes J; Baigent C
    Lancet; 2013 Aug; 382(9894):769-79. PubMed ID: 23726390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP; Deray G; Héloire F
    Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients?
    Nielsen OH; Ainsworth M; Csillag C; Rask-Madsen J
    Aliment Pharmacol Ther; 2006 Jan; 23(1):27-33. PubMed ID: 16393277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatotoxicity induced by coxibs: how concerned should we be?
    Bessone F; Hernandez N; Roma MG; Ridruejo E; Mendizabal M; Medina-Cáliz I; Robles-Díaz M; Lucena MI; Andrade RJ
    Expert Opin Drug Saf; 2016 Nov; 15(11):1463-1475. PubMed ID: 27537326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coxib's Safety in Patients with Inflammatory Bowel Diseases: A Meta-analysis.
    Ribaldone DG; Fagoonee S; Astegiano M; De Angelis C; Smedile A; Caviglia GP; Petrini E; Greco A; Pellicano R
    Pain Physician; 2015 Nov; 18(6):599-607. PubMed ID: 26606012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.